determining the effect of magnesium,vitamin b6 and b6-magnesium combination on premenstrual syndrome in the affected persons that going to medical health centers of isfahan university

comparison of magnesium,vitamin b6 and b6-magnesium combination on premenstrual syndrome in the affected persons that going to medical health centers of isfahan university

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106216854N1

Enrollment

170

Registered

2011-07-19

Start date

2010-04-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premenstrual syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: Magnesium That consist of magnesium oxide (MgO) powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 250 milligra

Treatment - Drugs

Placebo

Magnesium That consist of magnesium oxide (MgO) powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 250 milligram magnesium tab

vitamin B6: Magnesium That consist of pyridoxine powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 40 milligram vitamin B6 t

placebo That consist of starch and Drug faculty of Isfahan University will make these productions in the shape of tablet.the patients will use one tablet daily.

magnesium+vitamin b6 That consist of pyridoxine +magnesium oxide(MgO)powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criterial: The study population will be women of 45-15 referred to the selected health centers; who were affected by the PMS according to the criteria of American Psychiatry Association; and also met the inclusion criteria; being 45-15 years old; having regular menstrual cycle; not being affected by depression or anxiety; not having an acute or chronic disease; not taking medicines or supplements; and not taking regular exercise) exclusion criterial: will be pregnancy; willingness to use hormonal contraceptive methods or taking hormonal treatment; not taking the drug or not filling out the forms regularly; and unwillingness to continue the treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Premenstrual syndrome severity. Timepoint: 2 month before and 2 month after intervention. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNahid Fathizadeh

Isfahan university of medical science

Fathizadeh@nm.mui.ac.ir+98 913 100 4312

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026